english.prescrire.org > Spotlight > Archives : 2023 > Nirsevimab (Beyfortus°) to prevent RSV infection in infants

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Nirsevimab (Beyfortus°) to prevent RSV infection in infants

 Marketing Authorisations   Palivizumab was the first drug to receive European marketing authorisation for the prevention of RSV infection. Its use is restricted to certain infants at increased risk of developing severe disease. Nirsevimab, another monoclonal antibody directed against the RSV F protein, has been authorised for the prevention of RSV infection in neonates and infants, including those who have no risk factors for developing severe disease. Does nirsevimab reduce the incidence of severe RSV disease or death compared with palivizumab in infants with risk factors, or compared with placebo in healthy full-term infants?
Full article (3 pages) available for download by subscribers

©Prescrire 1 December 2023

Source: "Nirsevimab (Beyfortus°) to prevent RSV infection in infants. For infants at risk of developing severe disease: more convenient than palivizumab" Prescrire Int 2023; 32 (254): 285-287. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Palivizumab: moderate
reduction in hospitalisation
rate"
Prescrire Int 2004;
13 (74): 213-216.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's Spotlight